# Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

> **NCT01165268** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT01165268
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01165268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01165268, "Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01165268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*